Acorda Therapeutics (ACOR) Tops Q2 EPS by 7c
Get Alerts ACOR Hot Sheet
Price: $0.66 --0%
Revenue Growth %: +63.1%
Financial Fact:
Research and development: 54.78M
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: +63.1%
Financial Fact:
Research and development: 54.78M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of $0.19, $0.07 better than the analyst estimate of $0.12. Revenue for the quarter came in at $65.28 million versus the consensus estimate of $66.29 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seagate Technology (STX) Tops Q3 EPS by 4c; offers Q4 guidance
- Visa (V) Tops Q2 EPS by 7c, offers guidance
- Avangrid (AGR) Tops Q1 EPS by 19c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!